Literature DB >> 9201101

Effects of mixed ETA and ETB-receptor antagonist (Ro-47-0203) on hepatic microcirculation after warm ischemia.

T A Koeppel1, T Kraus, J C Thies, M M Gebhard, G Otto, S Post.   

Abstract

There is evidence that endothelin (ET) is involved in disturbances of the hepatic microcirculation after warm ischemia. In this study we investigated the influence of a mixed ETA-, ETB-receptor antagonist (Bosentan) on ischemia-reperfusion damage of the liver by means of intravital fluorescence microscopy (IVM). Clamping of the left liver lobe (= warm ischemia) was performed in 16 male Wistar rats for 70 min. The treatment group (N = 8) received 15 mg/kg Bosentan (Ro-47-0203) 1 min prior to reperfusion. Controls (N = 8) received an equivalent amount of Ringer's solution. Between 20 and 90 min after reperfusion, leukocyte-endothelial cell interactions in sinusoids and postsinusoidal venules as well as perfusion of hepatic acini were studied. Application of Bosentan improved sinusoidal blood flow, attenuated manifestations of microvascular perfusion failure, and decreased the number of rolling leukocytes in postsinusoidal venules. Our results provide further evidence that ET is involved in postischemic impairment of hepatic microhemodynamics during reperfusion.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9201101     DOI: 10.1023/a:1018830929913

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  27 in total

1.  Differential impact of Carolina rinse and University of Wisconsin solutions on microcirculation, leukocyte adhesion, Kupffer cell activity and biliary excretion after liver transplantation.

Authors:  S Post; P Palma; M Rentsch; A P Gonzalez; M D Menger
Journal:  Hepatology       Date:  1993-12       Impact factor: 17.425

2.  Timing of arterialization in liver transplantation.

Authors:  S Post; P Palma; A P Gonzalez; M Rentsch; M D Menger
Journal:  Ann Surg       Date:  1994-11       Impact factor: 12.969

3.  Response of plasma and tissue endothelin-1 to liver ischemia and its implication in ischemia-reperfusion injury.

Authors:  E Kawamura; N Yamanaka; E Okamoto; F Tomoda; K Furukawa
Journal:  Hepatology       Date:  1995-04       Impact factor: 17.425

4.  Hepatic resection with ischemia of the liver exceeding one hour.

Authors:  C Huguet; A Gavelli; S Bona
Journal:  J Am Coll Surg       Date:  1994-05       Impact factor: 6.113

5.  Hepatic effects of endothelin. Receptor characterization and endothelin-induced signal transduction in hepatocytes.

Authors:  C R Gandhi; R H Behal; S A Harvey; T A Nouchi; M S Olson
Journal:  Biochem J       Date:  1992-11-01       Impact factor: 3.857

6.  Effect of endothelin-1 on neutrophil adhesion to endothelial cells and perfused heart.

Authors:  A López Farré; A Riesco; G Espinosa; E Digiuni; M R Cernadas; V Alvarez; M Montón; F Rivas; M J Gallego; J Egido
Journal:  Circulation       Date:  1993-09       Impact factor: 29.690

7.  Hepatic microcirculatory perfusion failure is a determinant of liver dysfunction in warm ischemia-reperfusion.

Authors:  B Vollmar; J Glasz; R Leiderer; S Post; M D Menger
Journal:  Am J Pathol       Date:  1994-12       Impact factor: 4.307

8.  Impact of leukocyte-endothelial cell interaction in hepatic ischemia-reperfusion injury.

Authors:  B Vollmar; M D Menger; J Glasz; R Leiderer; K Messmer
Journal:  Am J Physiol       Date:  1994-11

9.  Effect of anti-tumor necrosis factor alpha on leukocyte adhesion in the liver after hemorrhagic shock: an intravital microscopic study in the rat.

Authors:  I Marzi; M Bauer; A Secchi; S Bahrami; H Redi; G Schlag
Journal:  Shock       Date:  1995-01       Impact factor: 3.454

10.  Hepatic release of endothelin-1 after warm ischemia. Reperfusion injury and its hemodynamic effect.

Authors:  S Nakamura; R Nishiyama; A Serizawa; Y Yokoi; S Suzuki; H Konno; S Baba; H Muro
Journal:  Transplantation       Date:  1995-03-15       Impact factor: 4.939

View more
  4 in total

Review 1.  Hypoxic hepatitis - epidemiology, pathophysiology and clinical management.

Authors:  Valentin Fuhrmann; Bernhard Jäger; Anna Zubkova; Andreas Drolz
Journal:  Wien Klin Wochenschr       Date:  2010-03       Impact factor: 1.704

2.  Bosentan, an endothelin antagonist, augments hepatic graft function by reducing graft circulatory impairment following ischemia/reperfusion injury.

Authors:  R Ricciardi; B K Schaffer; S A Shah; S H Quarfordt; B F Banner; S M Wheeler; S E Donohue; W C Meyers; R S Chari
Journal:  J Gastrointest Surg       Date:  2001 May-Jun       Impact factor: 3.452

3.  Endothelin A receptor blockade reduces hepatic ischemia/reperfusion injury after warm ischemia in a pig model.

Authors:  Dirk Uhlmann; Barbara Armann; Gabor Gaebel; Stefan Ludwig; Jochen Hess; Uta Carolin Pietsch; Evelyn Escher; Martin Fiedler; Andrea Tannapfel; Johann Hauss; Helmut Witzigmann
Journal:  J Gastrointest Surg       Date:  2003 Mar-Apr       Impact factor: 3.452

4.  Tezosentan, a novel endothelin receptor antagonist, markedly reduces rat hepatic ischemia and reperfusion injury in three different models.

Authors:  Douglas G Farmer; Fady Kaldas; Dean Anselmo; Masamichi Katori; Xiu-Da Shen; Charles Lassman; Marian Kaldas; Martine Clozel; Ronald W Busuttil; Jerzy Kupiec-Weglinski
Journal:  Liver Transpl       Date:  2008-12       Impact factor: 5.799

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.